Therapeutic Asset Ratings

548 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Bendamustine Advanced Solid Tumor	Fate Therapeutics	P2	CCC (54)
DALPICICLIB ISETIONATE Advanced Solid Tumor	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (54)
Famitinib Advanced Solid Tumor	Shanghai Hengrui Pharmaceutical Co., Ltd.	P2	CCC (54)
gh21 Advanced Solid Tumor	Suzhou Genhouse Bio Co., Ltd.	P2	CCC (54)
Trastuzumab Deruxtecan Advanced Solid Tumor	Baptist Health South Florida	P2	CCC (54)
Entrectinib Advanced Solid Tumor	Cancer Research UK	P2/3	CCC (54)
hx009 Advanced Solid Tumor	Hangzhou Hanx Biopharmaceuticals, Ltd.	P2	CCC (53)
prl3-zumab Advanced Solid Tumor	National Cancer Centre, Singapore	P2	CCC (53)
Mitoxantrone Advanced Solid Tumor	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	P1/2	CCC (53)
Niraparib Advanced Solid Tumor	LaNova Medicines Limited	P2	CCC (52)
gfh018 Advanced Solid Tumor	Genfleet Therapeutics (Shanghai) Inc.	P1/2	CCC (52)
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER Advanced Solid Tumor	Regeneron Pharmaceuticals	P1/2	CCC (52)
Nedaplatin Advanced Solid Tumor	Wigen Biomedicine Technology (Shanghai) Co., Ltd.	P2/3	CCC (52)
Ribociclib Advanced Solid Tumor	OnKure, Inc.	P1/2	CCC (52)
vx-970 Advanced Solid Tumor	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	P1/2	CCC (52)
Omeprazole Advanced Solid Tumor	Genentech, Inc.	P1	CCC (51)
Avelumab Advanced Solid Tumor	Inimmune Corporation	P3	CCC (50)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) Advanced Solid Tumor	Astellas Pharma Global Development, Inc.	P2	CCC (50)
es014 Advanced Solid Tumor	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (50)
fda022-bb05 Advanced Solid Tumor	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.	P2	CCC (50)
Gm-Csf Advanced Solid Tumor	China-Japan Friendship Hospital	P2	CCC (50)
hs-20093 Advanced Solid Tumor	Hansoh BioMedical R&D Company	P2	CCC (50)
IMMUNOGLOBULIN G1 (134-CYSTEINE,228-VALINE,242-PHENYLALANINE,243-GLUTAMIC ACID,339-SERINE,362-CYSTEINE,374-TRYPTOPHAN), ANTI-(HUMAN CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4) (HUMAN MONOCLONAL MEDI5752 .GAMMA.1-CHAIN), DISULFIDE WITH (122-CYSTEINE,212-VALINE) HUMAN MONOCLONAL MEDI5752 .LAMBDA.-CHAIN, (234->231')(237->234')(362->354') TRIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 (239-PHENYLALANINE,240-GLUTAMIC ACID,336-SERINE,354-CYSTEINE,371-SERINE,373-ALANINE,412-VALINE) ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN-MUS MUSCULUS MONOCLONAL MEDI5752 .GAMMA.1-CHAIN) DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL MEDI5752 .KAPPA.-CHAIN Advanced Solid Tumor	Institut Bergonié	P2	CCC (50)
Irpagratinib Advanced Solid Tumor	Beijing InnoCare Pharma Tech Co., Ltd.	P2	CCC (50)
Neratinib Advanced Solid Tumor	University Health Network, Toronto	P2	CCC (50)

Showing 26 to 50 of 548 assets

PreviousPage 2 of 22Next